LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

NCT03101254 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: LY3022855
DRUG: Vemurafenib
DRUG: Cobimetinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]